146 patents
Utility
CARM1 Inhibitors and Uses Thereof
28 Dec 23
Richard Chesworth, Oscar Miguel Moradei, Gideon Shapiro, Lei Jin, Robert E. Babine
Filed: 23 Nov 22
Utility
Carm1 inhibitors and uses thereof
5 Dec 23
Richard Chesworth, Oscar Miguel Moradei, Gideon Shapiro, Lei Jin, Robert E. Babine
Filed: 18 Mar 20
Utility
Combination Therapies with EHMT2 Inhibitors
16 Nov 23
The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof.
John Emmerson CAMPBELL, Kenneth William DUNCAN, Maria Alejandra RAIMONDI, Christine KLAUS, Elayne PENEBRE
Filed: 23 Mar 23
Utility
Myst Family Histone Acetyltransferase Inhibitors
9 Nov 23
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan
Filed: 16 Feb 23
Utility
Use of EZH2 inhibitors for treating cancer
17 Oct 23
The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor.
Scott Ribich, Michael Thomenius
Filed: 1 Jun 17
Utility
SMARCA4 Inhibition for the Treatment of Cancer
21 Sep 23
The present disclosure provides methods of determining a response to at least one therapy by a subject having cancer, wherein the at least one therapy comprises the administration of at least one SMARCA4-targeting compound.
Allison E. DREW, Lindsey Wood EICHINGER
Filed: 17 Jun 21
Utility
Methods of Synthesizing Substituted Purine Compounds
14 Sep 23
The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Edward J. OLHAVA
Filed: 14 Dec 22
Utility
Methods of synthesizing substituted purine compounds
12 Sep 23
The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Edward James Olhava
Filed: 5 Apr 21
Utility
CorrectedCARM1 Inhibitors and Uses Thereof
7 Sep 23
Richard Chesworth, Oscar Miguel Moradei, Gideon Shapiro, Lei Jin, Robert E. Babine
Filed: 18 Mar 20
Utility
Inhibitors of EZH2 and Methods of Use Thereof
29 Jun 23
The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor.
Stephen BLAKEMORE, Scott Richard DAIGLE
Filed: 13 Jun 18
Utility
Use of EZH2 Inhibitors for Treating Cancer
29 Jun 23
The present disclosure provides methods for the treatment of a cancer characterized by at least one tumor comprising intratumoral B cells and/or stromal B cells, in a subject, comprising administering to the subject an EZH2 inhibitor.
Carly CAMPBELL, Kat COSMOPOULOS, Alice MCDONALD, Melinda MERCHANT, Neil MICHAUD, Attila SZANTO
Filed: 27 May 21
Utility
MYST family histone acetyltransferase inhibitors
27 Jun 23
The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan
Filed: 29 Nov 18
Utility
Combination therapy for treating cancer
9 May 23
The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
Christine Klaus, Maria Alejandra Raimondi
Filed: 30 Mar 18
Utility
EZH2 inhibitors for treating lymphoma
9 May 23
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
Heike Keilhack, Sarah K. Knutson, Danielle Johnston Blackwell, Larisa Reyderman, Lone Ottesen
Filed: 4 Mar 20
Utility
Substituted benzene compounds
9 May 23
The present invention relates to substituted benzene compounds.
Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
Filed: 9 Jul 20
Utility
Method for treating cancer
9 May 23
The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
Heike Keilhack, Sarah K. Knutson
Filed: 21 Dec 20
Utility
Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor
4 May 23
Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide.
Kevin Wayne KUNTZ, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
Filed: 29 Sep 22
Utility
SETD2 Inhibitors and Related Methods and Uses, Including Combination Therapies
4 May 23
The present disclosure provides SETD2 protein inhibitors, and methods, compositions, and kits for treating diseases, disorders, or conditions in a subject with a SETD2 protein inhibitor and, optionally, a second therapeutic agent, wherein the second therapeutic agent comprises one or more glucocorticoid receptor agonists, one or more immunomodulatory drugs, one or more proteasome inhibitors, one or more Bcl-2 inhibitors, one or more pleiotropic pathway modulators, one or more XPO1 inhibitors, one or more histone deacetylase inhibitors, or one or more EZH2 inhibitors, or a combination thereof.
Maria Alejandra RAIMONDI, Jennifer Anne TOTMAN, Vinny MOTWANI, Katherine Louise COSMOPOULOS, John LAMPE
Filed: 19 Feb 21
Utility
Method of treating leukemia
25 Apr 23
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
Filed: 4 Jan 21
Utility
SMYD Inhibitors
30 Mar 23
Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
Filed: 22 Nov 21